Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers.

Autor: Michels RE; IQVIA, Real World Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. renee_michels@hotmail.com., Arteaga CH; HEOR Value Hub, Med-I-Mart BVBA/SPRL, Helshovenstraat 23, 3840, Hoepertingen, Belgium., Peters ML; IQVIA, Real World Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Van Herpen CML; Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands., Krol M; IQVIA, Real World Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands.

Publikováno v: Applied health economics and health policy [Appl Health Econ Health Policy] 2022 Sep; Vol. 20 (5), pp. 717-729. Date of Electronic Publication: 2022 Jul 18.

A Delphi panel on treatment of high disease activity relapsing remitting multiple sclerosis in the Netherlands.

Autor: Michels RE; Department of Real World & Analytics Solutions, IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands., Peters ML; Department of Real World & Analytics Solutions, IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands., Schiffers KM; Merck B.V., an affiliate of Merck KGaA, Darmstadt, Germany, Tupolevlaan 61, 1119 NW, Schiphol-Rijk, The Netherlands., Bouma PA; Department of Neurology, Tergooi Ziekenhuis, van Riebeeckweg 212, 1213 XZ, Hilversum, The Netherlands., Hengstman GI; Department of Neurology, Catharina Ziekenhuis, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands., van Munster CE; Department of Neurology, Amphia Ziekenhuis, Molengracht 21, 4818 CK, Breda, The Netherlands., Zeinstra E; Department of Neurology, Isala, Hoogeveenseweg 38, 7943 KA, Meppel, The Netherlands., Voer G; Merck B.V., an affiliate of Merck KGaA, Darmstadt, Germany, Tupolevlaan 61, 1119 NW, Schiphol-Rijk, The Netherlands., Krol M; Department of Real World & Analytics Solutions, IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands.

Publikováno v: Journal of comparative effectiveness research [J Comp Eff Res] 2021 Feb; Vol. 10 (2), pp. 93-100. Date of Electronic Publication: 2020 Dec 04.

Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.

Autor: Michels RE; IQVIA, Real World Evidence Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands., de Fransesco M; IQVIA, Real World Insights, Da Vincilaan 7, 1930, Zaventem, Belgium., Mahajan K; IQVIA, Real World Insights, Gurgaon, India., Hengstman GJD; Department of Neurology, Catharina Hospital, Michelangelolaan 2, 5623 EJ, Eindhoven, The Netherlands., Schiffers KMH; Merck B.V., Tupolevlaan 41-61, 1119 NW, Schiphol-Rijk, The Netherlands., Budhia S; PAREXEL International, PAREXEL Access Consulting, London, UK., Harty G; EMD Serono, a business of Merck KGaA, Boston, MA, USA., Krol M; IQVIA, Real World Evidence Solutions, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. mkrol@iqvia.com.

Publikováno v: Applied health economics and health policy [Appl Health Econ Health Policy] 2019 Dec; Vol. 17 (6), pp. 857-873.

Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy.

Autor: Zaidman, Craig M., Goedeker, Natalie L., Aqul, Amal A., Butterfield, Russell J., Connolly, Anne M., Crystal, Ronald G., Godwin, Kara E., Hor, Kan N., Mathews, Katherine D., Proud, Crystal M., Kula Smyth, Elizabeth, Veerapandiyan, Aravindhan, Watkins, Paul B., Mendell, Jerry R.

Publikováno v: Journal of Neuromuscular Diseases; 2024, Vol. 11 Issue 3, p687-699, 13p

Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review.

Autor: Gallehzan, Nasrin Abulhasanbeigi, Khosravi, Majid, Jamebozorgi, Khosro, Mir, Nazanin, Jalilian, Habib, Soleimanpour, Samira, Hoseini, Saeed, Rezapour, Aziz, Eshraghi, Abbas

Publikováno v: Health Economics Review; 2/16/2024, Vol. 14, p1-37, 37p